IBO:CC - Nick Karos to Present at H.C. Wainwright 1st Annual Mental Health Conference
(TheNewswire)
Calgary, AB – TheNewswire - June 24, 2022 – Universal Ibogaine Inc. (TSXV:IBO ) , ( OTC:IBOGF ) and ( FSE:JC4) (“ UI ” or the “ Company ”) a life sciences company with a mission totransform addiction treatment using medicalized ibogaine and a globallicensing model is pleased to announce that Nick Karos, CEO willpresent at the H.C. Wainwright 1 st Annual Mental Health Conference: Neuropsychiatry,Psychedelics and Beyond. The event is a hybrid online and in personevent scheduled for June 27, 2022.
About H.C.Wainwright
H.C. Wainwright & Co is one of theoldest and most trusted names in corporate finance in the USAproviding investment banking, corporate advisory, research, andanalysis covering sectors including Healthcare & Life Sciences,Mining, Cleantech, Shipping & Maritime andTechnology.
H.C. Wainwright hosts a robust calendarof conferences and events in the Healthcare sector. More informationand registration for the 1 st Annual Mental Health Conference can be found here .
Nick Karos CEO ofUniversal Ibogaine commented “H.C. Wainwright is a leader in the space and could be astrong strategic partner in our ongoing corporate finance roadmap. The opportunity to tell our story to this audience is anotherimportant step in developing the awareness around brand andoffering.
Correction Notice June13 Blue Digital Media
In UI’s June 13, 2022 News Release itwas stated that stock options to be granted to investor relationsadvisory firm Blue Digital Media would vest one-third at the end of each month in the 3 month term ofservice. Under TSXV Exchange Policy 4.4Security Based Compensation, stock options for investor relationsfirms must vest quarterly over a 12 month period with the firstvesting for 25% of the options at 3 months,25% at 6 months, 25% at 9months and the final 25% at 12 months.
About UniversalIbogaine Inc.
UI is a life sciences company, with a mission totransform addiction treatment using medicalized ibogaine through aplanned Canadian clinical trial focused on opioid use disorder, andultimately to utilize that protocol globally through planned futurelicensing agreements. UI is concurrently developing a state of the art holisticaddiction treatment protocol at its Kelburn Recovery Centre that, whenpaired with the planned ibogaine detox protocol, is intended torevolutionize the way we treat addiction and drastically improve thelives of individuals and families affected byaddiction.
NEITHER THE TSXVENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM ISDEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTSRESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THISRELEASE.
CAUTIONARY STATEMENTREGARDING FORWARD-LOOKING STATEMENTS
?This news release may containforward-looking statements and information. Forward-lookinginformation is frequently characterized by words such ?as"plans", "expect", "project","intend", "will", "believe","anticipate", "estimate", "scheduled",??"potential", or other similar words, or statementsthat certain events or conditions "may", "should"or ??"could" occur. The forward-looking statements andinformation are based on certain key expectations ?and assumptionsmade by UI. Although UI believes that the expectations andassumptions on which the forward-?looking statements are based arereasonable, undue reliance should not be placed on theforward-?looking statements because UI can give no assurance thatthey will prove to be correct.
Since ?forward-looking statementsaddress future events and conditions, by their very nature theyinvolve ?inherent risks and uncertainties. Actual results coulddiffer materially from those currently anticipated ?due to a number of factors andrisks, which include, but are not limited to, risks that required?regulatory approvals are not obtained. The reader is cautioned thatassumptions used in the ?preparation of such information, althoughconsidered reasonable by UI at the time of ?preparation, may proveto be incorrect and readers are cautioned not to place undue relianceon ?forward-looking information, which speaks only to conditions asof the date hereof. UI does not ?undertake any obligation torelease publicly any revisions to forward-looking informationcontained ?herein to reflect events or circumstances that occurafter the date hereof or to reflect the occurrence ?of unanticipatedevents, except as may be required under applicable securities laws.?
For furtherinformation:
InvestorRelations: Dugan Selkirk,IR Manager
dugan.selkirk@universalibogaine.com
Related Links
Copyright (c) 2022 TheNewswire - All rights reserved.